«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年05期

页码:

521-525

栏目:

临床医学

出版日期:

2023-09-20

文章信息/Info

Title:

The significance and mechanism of expression of neuromedin U protein in human papillary thyroid carcinoma

文章编号:

1006-8147（2023）05-0521-05

作者:

高关清¹; 郭丹²; 卢文亚¹; 张萍³; 王芳²; 石科²

（1.河南省第二人民医院耳鼻咽喉科，郑州 451191；2.河南医学高等专科学校生物化学与医学遗传学教研室， 郑州 451191；3.河南省第二人民医院普外科，郑州 451191）

Author(s):

GAO Guan-qing¹; GUO Dan²; LU Wen-ya¹; ZHANG Ping³; WANG Fang²; SHI Ke²

（1.Department of Otolaryngology，Henan Second Provincial People′s Hospital，Zhengzhou 451191，China；2.Department of Biochemistry and Medical Genetics，Henan Medical College，Zhengzhou 451191，China；3.Department of General Surgery，Henan Second Provincial People′s Hospital，Zhengzhou 451191，China）

关键词:

甲状腺乳头状癌; 免疫组化; 神经介素U蛋白; 肿瘤分期; 增殖

Keywords:

thyroid papillary carcinoma;  immunohistochemistry;  neuromedin U protein;  tumor stage;  proliferation

分类号:

R736.1

DOI:

-

文献标志码:

A

摘要:

目的：探讨神经介素U（NMU）蛋白在人甲状腺乳头状癌组织中的表达、临床意义及对细胞增殖的影响。方法：生物信息学分析GEPIA数据库中NMU在甲状腺乳头状癌组织及正常组织中的mRNA水平，并分析其表达与患者无病生存期的关系。进一步回顾性分析了来自河南省第二人民医院2016年3月—2022年3月接受手术治疗的71例患者的临床病理资料。采用免疫组化法检测甲状腺乳头状癌组织和正常组织中NMU蛋白表达水平，分析其与患者临床病理特征的关系。培养TPC-1和KTC-1细胞，通过NMU的shRNA质粒转染下调NMU表达，通过集落形成实验及噻唑蓝（MTT）实验检测对甲状腺乳头状癌细胞增殖的影响。结果：生物信息学分析揭示在GEPIA数据库中NMU的mRNA显著高表达，并与患者无病生存期显著相关。免疫组化揭示NMU在癌组织中显著高表达，而在正常组织中则为阴性或无表达，表达水平与肿瘤分期（高级别者42例，?字2=8.184，P=0.004）及多灶（33例，?字2=7.469，P=0.006）显著相关，而与患者的年龄、性别、淋巴结转移无关（均P>0.05）。MTT实验（t=7.33，P=0.005 2；t=8.08，P=0.004 0）及集落形成实验（t=12.43，P=0.001 1；t=16.46，P=0.000 5）证实，NMU在甲状腺乳头状癌细胞中的下调抑制甲状腺乳头状癌细胞增殖。结论：甲状腺乳头状癌组织中NMU显著高表达，且与患者侵袭性临床病理特征及无病生存有关，NMU蛋白促进甲状腺乳头状癌细胞增殖。

Abstract:

Objective： To investigate the expression and clinical significance of neuromedin U （NMU） protein in human thyroid papillary carcinoma tissues，as well as the effects on cell proliferation. Methods：The mRNA levels of NMU in thyroid papillary carcinoma tissues and corresponding normal tissues in GEPIA database were analyzed by bioinformatics，and the correlation between its expression and disease-free survival of patients was analyzed. The clinicopathologic data of 71 patients who received surgical treatment in the Second People′s Hospital of Henan Province from March 2016 to March 2022 were retrospectively analyzed. Immunohistochemistry was used to detect the expression levels of NMU protein in papillary thyroid carcinoma tissues and paracancer tissues，and the relationship between NMU protein expression and clinicopathologic features of patients was analyze. The expression of NMU was down-regulated by shRNA plasmid transfection in TPC-1 and KTC-1 cells，and the effects on the proliferation of thyroid papillary carcinoma cells were detected by colony formation assay and thiazolyl tetrazolium（MTT） assay. Results：Bioinformatics analysis revealed that NMU mRNA was significantly overexpressed in GEPIA database，and was significantly correlated with disease-free survival. Immunohistochemistry revealed significantly high expression of NMU in cancer tissues，while negative or no expression in paracancer tissues. The expression level was significantly correlated with tumor stage（42 cases with high grade，?字2=8.184，P=0.004） and multiple foci （33 cases with ?字2=7.469，P=0.006），but not with patient age，sex，and lymph node metastasis（all P>0.05）. Both MTT （t=7.33，P=0.005 2；t=8.08，P=0.004 0） and colony formation assays（t=12.43，P=0.001 1；t=16.46，P=0.000 5） confirmed that down-regulation of NMU in thyroid papillary carcinoma cells inhibited cell proliferation. Conclusion：NMU is highly expressed in thyroid papillary carcinoma tissues，which is related to clinicopathological features and disease-free survival of patients. NMU promotes proliferation of thyroid papillary carcinoma cells.

参考文献/References:

[1] MIRANDA-FILHO A，LORTET-TIEULENT J，BRAY F，et al. Thyroid cancer incidence trends by histology in 25 countries：a population-based study[J]. Lancet Diabetes Endocrinol，2021，9：225-234.
[2] LIN R X，YANG S L，JIA Y，et al. Epigenetic regulation of papillary thyroid carcinoma by long non-coding RNAs[J]. Semin Cancer Biol，2022，83：253-260.
[3] HARRIES V，WANG L Y，MCGILL M，et al. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?[J]. Surgery，2020，167：10-17.
[4] BERGDORF K，FERGUSON DC，MEHRAD M，et al. Papillary thyroid carcinoma behavior：clues in the tumor microenvironment[J]. Endocr Relat Cancer，2019，26：601-614.
[5] DE PRINS A，VAN EECKHAUT A，SMOLDERS I，et al. Neuromedin U and structural analogs：an overview of their structure，function and selectivity[J]. Curr Med Chem，2020，27：6744-6768.
[6] YE Y，LIANG Z ，XUE L. Neuromedin U：potential roles in immunity and inflammation[J]. Immunology，2021，162：17-29.
[7] DOGGRELL S A. Neuromedin U-a new target in obesity[J]. Expert Opin Ther Targets，2005，9：875-877.
[8] PRZYGODZKA P，SOBOSKA K，SOCHACKA E，et al. Neuromedin U：a small peptide in the big world of cancer[J]. Cancers（Basel），2019，11（9）：1312.
[9] PRZYGODZKA P，SOBOSKA K，SOCHACKA E，et al. Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment[J]. Cell Commun Signal，2022，20：193.
[10] WU Y，MCROBERTS K，BERR SS，et al. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation，lung metastasis and cancer cachexia[J]. Oncogene，2007，26：765-773.
[11] FILETTI S，DURANTE C，HARTL D，et al. Thyroid cancer：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-updagger[J]. Ann Oncol，2019，30：1856-1883.
[12] LI Y，GAO Y，CHU W，et al. Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma[J]. Aging （Albany NY），2021，13：23672-23688.
[13] HEDRICK J A，MORSE K，SHAN L，et al. Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U[J]. Mol Pharmacol，2000，58：870-875.
[14] MALENDOWICZ L K，RUCINSKI M. Neuromedins NMU and NMS：an updated overview of their functions[J]. Front Endocrinol （Lausanne），2021，12：713961.
[15] FERRARI S M，FALLAHI P，GALDIERO M R，et al. Immune and inflammatory cells in thyroid cancer microenvironment[J]. Int J Mol Sci，2019，20（18）：4413.

相似文献/References:

[1]索晓鹏,何小玲,何向辉,等. 甲状腺乳头状癌滤泡亚型声像图及临床病理特征分析[J].天津医科大学学报,2015,21(02):154.
　SUO Xiao-peng,HE Xiao-ling,HE Xiang-hui,et al.Analysis of ultrasonography and clinical pathological characteristics of follicular variant of papillary thyroid carcinoma[J].Journal of Tianjin Medical University,2015,21(05):154.
[2]谷 寅,何向辉,赵 科. 结节性甲状腺肿合并偶发乳头状癌临床分析[J].天津医科大学学报,2015,21(03):245.
　GU Yin,HE Xiang-Hui,ZHAO Ke.Incidental papillary carcinoma in nodular goiter[J].Journal of Tianjin Medical University,2015,21(05):245.
[3]林宪仁,何 佳,巴 一,等.Girdin蛋白在脑胶质瘤组织中的表达及其与临床病理特征和预后的关系[J].天津医科大学学报,2015,21(05):397.
　LIN Hsien-jen,HE Jia,BA Yi,et al.Expression of Girdin in glioma tissues and its relationship with pathological clinical characteristics and prognosis of the patient[J].Journal of Tianjin Medical University,2015,21(05):397.
[4]赵庆庆,宋文静.NF-κB和eIF4E在子宫内膜上皮内瘤变和子宫内膜样癌中的表达及意义[J].天津医科大学学报,2016,22(06):483.
　ZHAO Qing-qing,SONG Wen-jing.Expression and significance of NF-B and eIF4E in endometrial intraepithelial neoplasia and endometrioid carcinoma[J].Journal of Tianjin Medical University,2016,22(05):483.
[5]李 娜,李洪林,尹利荣.HPV E6/E7 mRNA与YAP在宫颈癌中的表达与相关性研究[J].天津医科大学学报,2018,24(04):307.
　LI Na,LI Hong-lin,YIN Li-rong.HPV E6/E7 mRNA and YAP expression and their correlation in cervical carcinoma[J].Journal of Tianjin Medical University,2018,24(05):307.
[6]彭泽椿,郑向前,高 明.甲状腺乳头状癌临床病理学特征与肥胖的相关性研究[J].天津医科大学学报,2018,24(05):429.
　PENG Ze-chun,ZHENG Xiang-qian,GAO Ming.Correlation between body mass index and clinicopathological characteristics of papillary thyroid carcinoma[J].Journal of Tianjin Medical University,2018,24(05):429.
[7]闫云飞,刘娜,叶贝贝,等.喉前淋巴结与甲状腺乳头状癌颈部淋巴结转移的相关性研究[J].天津医科大学学报,2021,27(04):369.
　YAN Yun-fei,LIU Na,YE Bei-bei,et al.Correlation between delphian lymph node and cervical lymph node metastasis of papillary thyroid carcinoma[J].Journal of Tianjin Medical University,2021,27(05):369.
[8]李广宁,曹文枫,齐丽莎,等.73例卵黄囊瘤临床病理分析[J].天津医科大学学报,2021,27(05):511.
　LI Guang-ning,CAO Wen-feng,QI Li-sha,et al.Clinicopathological analysis of 73 cases of yolk sac tumor[J].Journal of Tianjin Medical University,2021,27(05):511.
[9]张泽武,张伟.ARID1A表达与肝内胆管癌免疫细胞浸润及预后的相互关系研究[J].天津医科大学学报,2022,28(05):466.
　ZHANG Ze-wu,ZHANG Wei.Correlation of ARID1A expression with immune cell infiltration and prognosis of intrahepatic cholangiocarcinoma[J].Journal of Tianjin Medical University,2022,28(05):466.
[10]刘芬,李世宾,李晓石.人着丝粒蛋白E在人肾透明细胞癌中的表达及对细胞增殖的影响[J].天津医科大学学报,2023,29(06):594.
　LIU Fen,LI Shi-bin,LI Xiao-shi.Expression of human centromere protein E in human renal clear cell carcinoma and its effects on the cell proliferation[J].Journal of Tianjin Medical University,2023,29(05):594.

备注/Memo

备注/Memo:

基金项目 河南省科技攻关项目（222102310338）
作者简介 高关清（1983-），男，主治医师，硕士，研究方向：头颈疾病尤其是肿瘤的防治和诊疗等；E-mail：guanqinggao@163.com。

常用功能

更新日期/Last Update: 2023-09-25